V

Vanda Pharmaceuticals

D
VNDA
USD
0.125
(2.5562%)
Market Closed
42,646.00
Volume
0.51
EPS
-
Div Yield
-26.394737
P/E
292,323,387.12
Market Cap
Today
5.3571%
1 Week
7.618%
1 Month
11.321%
6 Months
-8.402%
12 Months
12.950%
Year To Date
19.121%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALKS
-0.32
(-1.0925%)
USD
I
INCY
1.47
(1.8173%)
USD
AMGN
AMGN
0.28
(0.087%)
USD
GILD
GILD
6.23
(6.7946%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
AZN
AZN
0.335
(0.5207%)
USD
J
JAZZ
7.55
(6.7713%)
USD
S
SGMO
0.33
(13.3603%)
USD
C
CRBP
-0.36
(-1.9027%)
USD
A
ACAD
1.42
(8.993%)
USD

Title:
Vanda Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Do you need help or have a question?
Contact Us